Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal of hematology & oncology·2026
Same author

Lung cysts, a common feature found in patients with hairy cell leukaemia and Langerhans cell histiocytosis.

ERJ open research·2026
Same author

CircRNAs derived from the tyrosine phosphatase PTPN22 impact chemosensitivity in ALK-positive T-cell lymphomas.

Scientific reports·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026
Same author

Clonal Lymphocyte Expansions and JAK-STAT Pathway Mutations Define a Pathogenic Continuum Driving Resistance to Gluten-Free Diet in Celiac Disease.

Gastroenterology·2026
Same author

Hematological immune-related adverse events associated with checkpoint inhibitors.

Cancer treatment reviews·2026

Related Experiment Video

Updated: May 16, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Mast cell leukemia.

Sophie Georgin-Lavialle1, Ludovic Lhermitte, Patrice Dubreuil

  • 1Centre de Référence des Mastocytoses, Faculté de Médecine et Assistance Publique-Hopitaux de Paris (AP-HP) Necker-Enfants Malades, Paris, France.

Blood
|December 18, 2012
PubMed
Summary

Mast cell leukemia (MCL) is a rare, aggressive disease. Diagnosis requires specific mast cell percentages, and common markers are unreliable, necessitating gene sequencing for this challenging cancer.

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Related Experiment Videos

Last Updated: May 16, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Area of Science:

  • Hematology
  • Oncology

Background:

  • Mast cell leukemia (MCL) is an extremely rare and aggressive subtype of systemic mastocytosis.
  • It presents either as a new disease or secondary to pre-existing mastocytosis.
  • MCL shares more characteristics with systemic mastocytosis than acute myeloid leukemia.

Purpose of the Study:

  • To describe the clinicopathologic features of mast cell leukemia.
  • To highlight diagnostic challenges and therapeutic limitations.

Main Methods:

  • Review of clinicopathologic data for MCL cases.
  • Analysis of diagnostic criteria, including mast cell percentages in blood and bone marrow.
  • Evaluation of phenotypic markers and mutational analysis (KIT D816V).

Main Results:

  • MCL accounts for less than 1% of all mastocytosis cases.
  • Symptoms often involve systemic mast cell activation affecting organs like the liver and spleen.
  • Diagnostic criteria include ≥20% atypical mast cells in marrow or ≥10% in blood, with an aleukemic variant (<10% circulating mast cells).
  • Common phenotypic markers are unreliable; non-KIT D816V mutations are frequent, mandating complete gene sequencing.
  • Therapy is often ineffective, with a median survival of less than 6 months.

Conclusions:

  • Mast cell leukemia is a distinct and aggressive hematologic malignancy.
  • Accurate diagnosis requires careful assessment of mast cell burden and genetic mutations.
  • Further research into combination therapies and bone marrow transplantation is crucial for improving outcomes.